Category: 3. Business

  • Contacts with the China-Eurasia Economic Cooperation Fund

    Contacts with the China-Eurasia Economic Cooperation Fund

    On 10 February 2026, representatives of the Secretariat of the Shanghai Cooperation Organization visited the headquarters of the China-Eurasia Economic Cooperation Fund (CEECF) in Beijing.

    During the talks with CEECF CEO Chen Zhou, SCO Secretariat Counsellor Iskander Baitasov outlined cooperation within the Organization in the trade and economy, investment and financial spheres, highlighting priority tasks related to the implementation of the decisions of the SCO Tianjin Summit (1 September 2025) and other important agreements reached by the leaders of the member states.

    Special attention was paid to discuss the prospects of CEECF’s participation in the Organization’s project activities, as well as the practical cooperation with partners within the framework of the SCO Member States Investors Association and other platforms.

    Chen Zhou informed about the Fund’s priorities and strategy. Established by the initiative of the Government of the People’s Republic of China, the Fund serves as a platform for direct investment focused on the SCO region. The CEECF expressed interest in practical cooperation aimed at establishing ties with partners and co-investors from the “SCO community” countries, aligning prospective projects with the involvement of financial capital, including those implemented in a multilateral format, as well as holding joint public events.

    Contacts with the China-Eurasia Economic Cooperation Fund

    China-Eurasia Economic Cooperation Fund (CEECF) is a state direct investment platform, with the Export-Import Bank of China as its majority shareholder. The launch of the CEECF was announced by President of the People’s Republic of China Xi Jinping in September 2014 at the meeting of the Council of Heads of State of the SCO in Dushanbe. The Fund’s priority investment areas include energy resources and downstream industries, agricultural development, logistics, infrastructure, information technology, manufacturing and other sectors. Currently the target investment capacity of the CEECF is USD 5 billion.

    Continue Reading

  • All in a day’s work for Louise Fraser

    All in a day’s work for Louise Fraser


    Louise Fraser’s functional assay R&D team. Top row: Natalie Morrell; Ines Vitoriano; Louise Fraser; Yang Cao. Bottom row: Sebastien Ricoult; Jess Moore; Jacqui Weir; Manisha Mullen | Photo: Michael Rowland

    February 11, 2026

    At 16, Fraser didn’t know what she wanted to do with her life. But she found an opportunity to work in a lab at a local university near her home in Bristol, England. There, she assisted with simple tasks like plating E. coli onto agar plates and preparing buffers. “I was really inspired to work in that environment because it’s cool, right?” she says. “I just really enjoyed technology, and science, and discovering new things.”

    That early exposure led her down the path to obtain a PhD in biochemistry. Academic research, however, felt a bit lonely. She preferred teamwork, and decided biotechnology might be a better fit. “It was actually quite hard to find somebody who would take you on as someone fresh out of your studies,” Fraser says. Fortunately, a scientist at Solexa—a DNA sequencing company that would later be acquired by Illumina in 2007—took a chance and hired her as an entry-level PhD scientist in the library prep group.

    After studying in the high-end laboratories of Imperial College London, moving into Solexa’s simple office space—housed in a loading bay for delivery trucks—was a shock. In the years following Illumina’s acquisition, Fraser saw incredible transformation: a surge in colleagues, new leadership, and expanded resources to push sequencing innovation further than ever before.

    Louise Fraser, Illumina Associate Director in Assay R&D | Photo: Michael Rowland

    She didn’t know that her first full-time job would turn into two decades at Illumina—where she is now an associate director in assay R&D and a force behind launching Illumina’s cutting-edge library prep solutions. Fraser is particularly excited about the upcoming commercial release of constellation, the Illumina mapped read sequencing technology that eliminates the entire up-front library preparation workflow for whole human genome sequencing.

    Constellation performs “tagmentation” on the flow cell surface—a process of binding, and fragmentation—which dramatically reduces hands-on prep time, lowers the potential to introduce errors, and allows reconstruction of longer genomic sequences through use of a brand new bioinformatic pipeline. It simplifies whole-genome sequencing, delivering Illumina’s most complete genome—and Fraser has been one of the scientific leaders bringing this innovation to life.

    “In order to get DNA into a state where it can go onto the sequencer, you currently have to do a library prep step, and that can be complicated. It requires expertise,” she explains. With constellation, the sequencer does all the hard work, and users can simply place DNA directly on the instrument—no library prep required.

    Because library prep occurs directly on the flow cell surface, DNA fragments physically close to one another on the original strand tend to remain close together on the flow cell. By applying advanced bioinformatics approaches, scientists can extract this “proximity” information to disentangle complex “dark” regions of the genome.

    The UK constellation team at the Illumina office in Cambridge. | Photo: Michael Rowland

    Recognizing women and girls in science

    The constellation team at Illumina includes over 100 scientists globally, each leveraging their unique expertise to develop the cutting-edge solution.

    February 11 is International Day of Women and Girls in Science, an annual event declared by the United Nations General Assembly in 2015. The 2026 theme centers around closing the gender gap in STEM. According to a 2024 report from UNESCO, retention of women in STEM is strongly influenced by institutional and workplace conditions.

    At this point in her career, Fraser doesn’t see gender as a defining part of her identity as a scientist or leader. “I work with a lot of amazing women scientists and men scientists,” she says. “And maybe, I’m lucky, right?” For Fraser, the norm is a mixed-gender team that treats each other with respect. But she sees how biases may deter younger girls from pursuing science.

    Battling bias for the younger generations

    A few years ago, Fraser and Vicki Thompson, a staff scientist on her team, were invited to present at a local primary school’s “Genomics 101 in the Classroom” event. Dressed in their lab coats, Fraser and Thomspon observed the one hundred young students as they filed into the assembly. “In the front row, one child said to another with absolute astonishment: ‘Oh my gosh, it’s two women,’” she recalls. “And we were shocked that they were expecting men.”

    For that student, Fraser and Thomson challenged some previously held assumptions about who can be a scientist. Representation still clearly matters. Giving women scientists opportunities to present their work can be eye-opening for young girls who may have never imagined themselves in a STEM career.

    “Science is for everybody.” Fraser says. “It doesn’t matter who you are, where you’re from—you just have to have a passion to go after it.”

    From her first agar plates to the launch of constellation, Fraser’s commitment to simplifying sequencing not only fuels this launch—it helps open doors for the next generation of scientists.

     

    Learn how mapped read technology works with Louise and discover the power of constellation.

    Continue Reading

  • Ascletis Selects Oral Amylin Receptor Peptide Agonist, ASC36, for Clinical Development

    –   Utilizing Ascletis’ Peptide Oral Transport ENhancement Technology (POTENT), ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state, in non-human primate (NHP) studies.

    –   In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after oncedaily dosing for 7 days. ASC36 tablets also reduced food intake significantly.

    –   In a head-to-head diet-induced obese (DIO) rat model, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively.

    –   ASC36 oral tablets are expected to utilize a lower dose due to potentially better oral bioavailability and efficacy. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing.

    –   Submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets is expected in the second quarter of 2026.

    HONG KONG, Feb. 10, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces that it has selected ASC36 oral tablets, its first oral amylin receptor peptide agonist, for clinical development. Ascletis expects to submit an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ASC36 oral tablets for the treatment of obesity in the second quarter of 2026.

    ASC36 oral tablets were developed with Ascletis’ proprietary Peptide Oral Transport ENhancement Technology (POTENT). In non-human primates (NHPs), 10 mg ASC36 oral tablet per animal dosed once daily for 7 days achieved absolute oral bioavailability[1] of 8% and elimination half-life of 116 hours at steady state; 25 mg ASC36 oral tablet per animal dosed once daily for 7 days  achieved absolute oral bioavailability of 6% and elimination half-life of 167 hours at steady state. The long elimination half-life (116 hours to 167 hours) of ASC36 oral tablets supports once-daily and less frequent oral dosing.

    ASC36 oral tablets demonstrated significant weight loss in both NHP and diet-induced obese (DIO) rat models. In NHPs, ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for 7 days. ASC36 tablets also reduced food intake significantly.

    In a head-to-head DIO rat model, after 7 days of treatment, ASC36 demonstrated approximately 32% and 91% greater relative body weight reduction compared to eloralintide and petrelintide, respectively. 

    ASC36 oral tablets are expected to utilize a lower dose, relative to a recently FDA approved oral GLP-1R peptide agonist, due to potentially better oral bioavailability and efficacy. This superior weight loss per milligram of ASC36 peptide may also provide scalability advantages in manufacturing.

    ASC36, an amylin receptor peptide agonist, was discovered and developed in-house utilizing Ascletis’ Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD). ASC36 oral tablet formulation was developed and optimized by Ascletis’ POTENT technology for delivery of oral peptides.

    “ASC36 oral tablets is an important amylin agonist among three key amylin drug candidates, i.e. an oral small molecule amylin, an oral peptide amylin and a once-monthly subcutaneous injectable peptide amylin,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. “Leveraging our three proprietary technology platforms, including AISBDD, Ultra-Long-Acting Platform (ULAP) and POTENT, Ascletis has successfully established a highly competitive, differentiated and diverse pipeline portfolio which can potentially effectively address the various treatment needs of patients with obesity and other metabolic diseases.”

    [1] Absolute oral bioavailability: the percentage of an orally administered drug that reaches the systemic circulation (bloodstream), compared to an intravenous (IV) dose of the same drug

    About Ascletis Pharma Inc.

    Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a small molecule GLP-1R agonist designed to be administered once daily orally and once monthly to once quarterly subcutaneously as a treatment therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

    For more information, please visit www.ascletis.com.

    Contact:

    Peter Vozzo
    ICR Healthcare
    443-231-0505 (U.S.)
    [email protected] 

    Ascletis Pharma Inc. PR and IR teams
    +86-181-0650-9129 (China)
    [email protected]
    [email protected] 

    SOURCE Ascletis Pharma Inc.

    Continue Reading

  • U.S. and Canada Chemistry Leaders Strengthen Responsible Care® through MOU

    U.S. and Canada Chemistry Leaders Strengthen Responsible Care® through MOU

    Washington, D.C., and Ottawa, Ontario (Feb. 10, 2025) – The American Chemistry Council (ACC) and the Chemistry Industry Association of Canada (CIAC) today renewed a Memorandum of Understanding (MOU) to enhance cross‑border collaboration and strengthen alignment of Responsible Care® certification across the chemical industry. 

    As the global chemical industry’s signature environmental, health, safety, and security initiative, Responsible Care has long served as a foundation for driving improved performance and building trust with communities, regulators, and value chain partners. Under the new MOU, CIAC will adopt the ACC Responsible Care Management System® (RCMS®)/RC14001® certification model as the exclusive pathway for CIAC member companies to meet their Responsible Care certification requirements.

    This announcement deepens the longstanding partnership between ACC and CIAC by supporting shared infrastructure, expanding auditor capacity, and enhancing harmonization of Responsible Care implementation across both countries. Both organizations will work closely to provide training, implementation support, certification documentation, and coordinate outreach to member companies and auditing bodies. This alignment will also streamline and optimize processes for multinational companies operating in both Canada and the United States. By unifying certification under the RCMS®/RC14001® model, companies will benefit from a more consistent Responsible Care® framework, reducing duplicative audits, simplifying internal management systems, and ensuring clearer expectations across borders.

    Chris Jahn, President & CEO of the American Chemistry Council noted, “Today’s agreement reflects our organizations’ continued, shared commitment to strengthening Responsible Care. By aligning around the RCMS® and RC14001® certification models, ACC and CIAC are reinforcing the consistent, rigorous expectations our industry embraces and demonstrating that continuous improvement, transparency, and safety leadership are the cornerstones of how we operate. Together, we’re building a safer, more competitive, and more resilient chemical industry.”

    Greg Moffatt, President & CEO of the Chemistry Industry Association of Canada, shared, “This MOU underscores the strong collaboration between Canada and the United States in advancing responsible, sustainable chemical manufacturing. CIAC pioneered Responsible Care more than four decades ago and our members remain deeply committed to the program’s principles of transparency, accountability, and continuous improvement. We’re proud to deepen our partnership with ACC as we work together to advance Responsible Care and support the safe, sustainable growth of our sector.”

    Continue Reading

  • Royal Caribbean Group Raises Dividend Fifty Percent

    Royal Caribbean Group Raises Dividend Fifty Percent

    MIAMI, Feb. 10, 2026 /PRNewswire/ — The Board of Directors of Royal Caribbean Group (NYSE: RCL) today declared a quarterly dividend of $1.50 per common share payable on April 3, 2026 to shareholders of record at the close of business on March 6, 2026. 

    “This dividend increase reflects the continued strength of our business and the momentum across our global vacation portfolio,” said Jason Liberty, President and CEO. “This step underscores our commitment to delivering meaningful returns to our shareholders while continuing to invest in the innovations and experiences that define Royal Caribbean Group.”

    About Royal Caribbean Group
    Royal Caribbean Group is a leading global vacation company spanning cruise, exclusive destinations, and land-based vacation experiences. The company operates 69 ships sailing to more than 1,000 destinations across all seven continents through its three wholly owned brands -Royal Caribbean, Celebrity Cruises, and Silversea – and a 50% joint venture interest in TUI Cruises which operates the Mein Schiff and Hapag-Lloyd brands.

    The Group is expanding its portfolio of private destinations from three to eight by 2028 through its Perfect Day and Royal Beach Club collections, and the company will enter river cruising in 2027 with Celebrity River Cruises. Powered by innovative brands, advanced technology, and an industry-leading loyalty program, the company has built a connected vacation ecosystem, turning the vacation of a lifetime into a lifetime of vacations.

    Named to the Fortune World’s Most Admired Companies 2026 list and to Forbes’ 2026 Best American Companies lists, Royal Caribbean Group is guided by its mission to deliver the best vacations responsibly. For more information, visit www.royalcaribbeangroup.com.

    SOURCE Royal Caribbean Group

    Continue Reading

  • India-UAE Air Travel Demand Could Go Unmet

    India-UAE Air Travel Demand Could Go Unmet

    This study finds that current air capacity between India and the United Arab Emirates is failing to keep pace with rising travel demand, potentially reducing the economic benefits that stronger air connectivity can support.

    Under existing capacity levels, up to 27% of forecast India–UAE passenger demand could go unserved by 2035. This would represent a cumulative shortfall of about 54.5 million journeys, including 13.2 million on the Abu Dhabi–India corridor alone.

    The report highlights strong structural growth in India’s aviation market. Their travelling class has grown from 24% of the population in 2010 to 40% in 2024, or nearly 300 million people. As a result, air travel demand is expected to grow by 7.2% per year through 2035, adding nearly 22 million passenger journeys annually.

    India–UAE air travel demand is growing rapidly, underpinned by rising incomes, expanding international trade, and increasing outbound and inbound tourism.
    – Matthew Dass, Director of Consulting

    The study also quantifies the economic impact of the UAE–India air corridor. With current capacity constraints, GDP contributions is expected to grow at a 3% CAGR over the next five years; easing constraints could lift growth to 5.5%–7%. Doubling Abu Dhabi–India seat capacity alone could generate an additional $7.2 billion in GDP over five years and support more than 170,000 jobs per year.

    Beyond immediate impacts, improved connectivity could contribute to productivity gains of up to $9 billion annually by 2035, support trade and investment, and put downward pressure on fares through increased capacity and competition.

    *The study was commissioned by Etihad Airways and conducted by Tourism Economics.

    Continue Reading

  • Infleqtion And NASA to Fly The World’s First Quantum Gravity Sensor to Space

    Infleqtion And NASA to Fly The World’s First Quantum Gravity Sensor to Space

    Insider Brief

    • Infleqtion is collaborating with NASA Jet Propulsion Laboratory on the Quantum Gravity Gradiometer Pathfinder mission to fly the first standalone quantum gravity sensor in low Earth orbit, with a planned launch around 2030.
    • The mission will demonstrate a neutral-atom quantum sensor that measures Earth’s gravitational field and gradients from space, enabling more sensitive tracking of mass changes in water, ice, and land than current methods.
    • Backed by more than $20 million in mission funding, QGGPf builds on NASA’s Cold Atom Lab and GRACE heritage to reduce risk for future space-based quantum sensing systems with applications in Earth science, navigation, and national security.

    PRESS RELEASE — Infleqtion, a global leader in quantum sensing and quantum computing powered by neutral-atom technology, announced its role as a collaborator on NASA’s Quantum Gravity Gradiometer Pathfinder (QGGPf) mission. Led by NASA’s Jet Propulsion Laboratory (JPL), the mission will fly the first quantum sensor capable of measuring the Earth’s gravitational field and its gradients; signals that are used today to monitor mass dynamics on the planet’s surface. The quantum instrument will be aboard a dedicated satellite in low Earth orbit (LEO). This program follows Infleqtion’s announcement to go public through a merger with Churchill Capital Corp X (NASDAQ: CCCX).

    The QGGPf mission is designed to demonstrate quantum sensor technologies that could transform how Earth’s gravity is measured from space. The quantum sensor is designed to monitor mass dynamics across the planet’s surface, including changes in water, ice and land, while operating in microgravity, which enables longer interaction times and correspondingly improved measurement sensitivities. As a technology pathfinder, the mission will help inform the design of future science-grade instruments, representing a major step forward in U.S. leadership in space-based quantum sensing and strategic intelligence.

    This project showcases what is possible when NASA and U.S. industry collaborate to push the boundaries of frontier science and technology. QGGPf builds on NASA’s long legacy of space-based gravity mapping and applies Infleqtion’s quantum engineering capabilities to enable a new class of measurement techniques designed specifically for the microgravity environment of space.

    A Quantum Leap in Geospatial Precision and Strategic Sensing

    With more than $20 million in contracted mission funding to date, the QGGPf mission, with contributions from NASA’s Goddard Space Flight Center, the University of Texas at Austin, Infleqtion, Monarch Quantum, and Jemba9, will fly the first standalone quantum gravity sensor in orbit.

    “Quantum sensing opens an entirely new domain for U.S. space leadership,” said Dana Anderson, Chief Science Officer at Infleqtion. “By deploying this technology in orbit, we are demonstrating the feasibility of quantum gravity sensing in space and laying the groundwork for future capabilities that can deliver unprecedented insight into our planet.”

    By directly measuring subtle variations in Earth’s gravitational field, the mission aims to demonstrate technologies that will help reduce risk for future quantum gravity instruments. These future systems could enable higher-resolution insights into how underground water, ice, and natural resources shift over time, critical data for understanding planetary health, strengthening national resilience, and supporting long-term economic and security planning. The one-year mission is expected to launch in 2030.

    Proven Quantum Heritage

    QGGPf builds on work done by JPL and Infleqtion on the Cold Atom Lab (CAL) program aboard the International Space Station, and on NASA’s long heritage mapping Earth’s gravitational field through the GRACE mission series.

    Infleqtion’s role on the QGGPf project includes the design, maturation, and integration of the quantum core of the sensor, encompassing its vacuum, laser, and control subsystems. The cold-atom system, based on ultracold rubidium atoms cooled to near absolute zero, is designed to enable direct gravity gradient measurements from space with unprecedented precision.

    Accelerating Quantum-to-Space Transition

    The mission further marks a significant milestone in America’s growing quantum ecosystem, showcasing how public–private relationships can accelerate the transition from fundamental research to operational capability. Beyond Earth science, quantum sensing in space will enable advances in navigation, resource management, and national security, where precision and autonomy are critical.

    NASA and Infleqtion plan to complete the instrument hardware development over the next three years, followed by flight demonstration.

    To learn more about how Infleqtion’s quantum technologies are enabling advances in space exploration, navigation, remote sensing, and defense, visit https://infleqtion.com/space-and-frontier/.

    Continue Reading

  • US consumer spending slowed in December – Is it a warning for the economy? – BBC

    US consumer spending slowed in December – Is it a warning for the economy? – BBC

    1. US consumer spending slowed in December – Is it a warning for the economy?  BBC
    2. Disappointing holiday season: December retail sales were flat, falling well short of estimate  CNBC
    3. Stock Rally Fades as Traders Brace for Data Deluge: Markets Wrap  Bloomberg.com
    4. The Dollar Slipped As US Shoppers Hit Pause  Finimize
    5. The unexpected U.S. retail data: Statistical noise or an economic crack?  富途牛牛

    Continue Reading

  • Kirkland Represents Axera on its Hong Kong IPO | News

    Kirkland & Ellis advised Axera Semiconductor Co., Ltd. (Axera, HKEX: 0600) on its global offering and listing on the Main Board of The Stock Exchange of Hong Kong Limited on February 10, 2026. The joint sponsors are China International Capital Corporation Hong Kong Securities Limited, Guotai Junan Capital Limited and BOCOM International (Asia) Limited.

    Axera successfully raised approximately HK$2.96 billion, prior to the exercise of the over-allotment option. The offering also attracted significant interest from a prestigious group of 16 cornerstone and industrial investors, including OmniVision, Youngor, Desay SV, Joyson Electronics, NGS Super, etc.

    Axera is a provider of AI inference SoCs, delivering cutting-edge perception and computing platforms for edge and endpoint AI applications. According to CIC, Axera ranked as the first in the mid-to-high-end visual on-device AI inference chips and fifth largest provider of visual on-device AI inference chips globally, and the third largest provider in China in the realm of edge AI inference in terms of shipment volume in 2024.

    The Kirkland team included capital markets lawyers Mengyu Lu, George Zheng, Justin Zhou, Yuchen Han, Jiawei Zhao, Luna Wang and Patty Zhu.

    Continue Reading

  • New Qatar law encourages amicable settlement of state claims

    New Qatar law encourages amicable settlement of state claims

    Pamela McDonald of Pinsent Masons was commenting after Qatar’s cabinet published its Decision of the Council of Ministers on Regulating Procedures for Filing Lawsuits Related to Government Entities, which requires public authorities in Qatar to take active steps to settle disputes before formally requesting to initiate a lawsuit.

    The decision, published on 2 February in the Official Gazette, states that any “government entity must, before requesting to initiate a Lawsuit, take initiatives for reconciliation and settlement”. The decision defines a “lawsuit” as “a dispute or claim brought by or against the government entity”. 

    The law imposes a statutory obligation on all government entities and public bodies to make and document settlement efforts prior to escalation. They will be required to provide all necessary documents, records, information or data in order to obtain approval from the Department of State Affairs at the Ministry of Justice to initiate the lawsuit.

    Where settlement is achieved, the ministerial department will ensure parties fulfil their obligations in accordance with the agreed terms.

    The law also states that, if settlement efforts are unsuccessful, the public authority must refer the request to initiate the lawsuit and also provide documents and records, including an explanation for why reconciliation and settlement was not possible.

    Article 3 of the decision sets out that, after obtaining the relevant approval, the minister, head of the relevant government body or authority may initiate settlement efforts at any stage of a claim process.

    There are two limitations on permission for lawsuits outlined in article 5. These state that permission will not be given if the value of the claim does not exceed QAR 50,000, or if there is insufficient documentation and evidence necessary to support the lawsuit.

    McDonald, a specialist in international arbitration, said the new law was a “helpful development” in Qatar’s dispute resolution landscape and “will be attractive to prospective and current foreign investors in Qatar’s economy.”

    The law is particularly crucial because government entities in Qatar often play an important role in initiating a lawsuit even where they are the defendant or respondent party. This is a result of article 2.2 of Qatar’s Arbitration Law of 2017, which requires arbitration agreements in contracts with a public entity to be approved by the prime minister to be deemed valid. 

    This can result in the authority requesting the prime minister’s office for approval to arbitrate claims being advanced against it. Read in this context, McDonald says the decision’s reference to the government entity “requesting to initiate a Lawsuit” can refer to claims that a public authority wishes either to prosecute or defend.

    She also said the decision is yet another demonstration of Qatar’s ongoing commitment to supporting alternative dispute resolution methods since the introduction of a dedicated mediation law in November 2021. “Helpfully, article 4 of the decision references both general reconciliation efforts as well as the use of mediation,” she added. “This further underlines Qatar’s emphasis on the importance of mediation as an alternative dispute resolution method.”

    Continue Reading